Compound E, chemically designated as 209986-17-4 (CAS), represents a significant study within the field of Alzheimer's disease research. This γ-secretase blocking agent was initially developed as a promising therapeutic approach aimed at reducing the synthesis of amyloid-beta peptides, which are believed to be key contributors to the formation of